Orivam News from the source.

Rubicon Research Limited

NSE RUBICON BSE 544578 INE506V01022

0 filings · 0 analysed

1,771.70 +86.39% over 6 months
1,000 1,250 1,500 1,750 May 26 Jun 26 Jul 26 Aug 26 Oct 26
  1. HEALTHCARE MOFSL PR PG024

    Investment Guru India Buy +0.00% in 1h

    The report expects Rubicon to outperform in the US market with 22% YoY growth and names it a top idea for R&D-led growth, forecasting EBITDA growth of 38% YoY.

Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.

What the desks said

03 Oct 2026, 15:02 IST Motilal Oswal (MOFSL) via Investment Guru India Buy

The report expects Rubicon to outperform in the US market with 22% YoY growth and names it a top idea for R&D-led growth, forecasting EBITDA growth of 38% YoY.

Read this note →

Announcement timeline

No filings stored for this company yet.

Never miss the next one.

Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.

Get the daily brief